Abingworth raises $356M to invest in late-stage drug development

Transatlantic venture capital group Abingworth has raised $356 million to invest in late-stage drug development by pharmaceutical and biotechnology companies.
Announced Monday, the new fund is part of Abingworth’s “clinical co-development” strategy, which it started in 2009 and has used to support 14 programs to date, including with partners like AstraZeneca, Eisai and Pfizer.